Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
Celgene
Search
Federal judge dismisses longstanding suit over Bristol Myers' $74B Celgene buyout
7 months ago
Pharma
Law
Ex-Celgene chief Mark Alles, former Goldfinch Bio leader Tony Johnson are back in the game as CEOs
Last year
People
Peer Review
Bristol Myers Squibb and Celgene named in class action suit over cancer blockbuster Pomalyst
Last year
Pharma
Law
Bristol Myers inks protein degrader deal via Celgene team's link to seed-stage biotech
3 years ago
Startups
Deals
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
3 years ago
Pharma
Law
Bristol Myers dusts off an old Celgene chemotherapy for use in children with a rare blood cancer
3 years ago
Pharma
FDA+
Bristol Myers sued over $6B Celgene CVR as trustee claims 'blatant misconduct' for liso-cel delays
4 years ago
Pharma
Bristol Myers gets its first GI drug approval, and it comes from a longtime Celgene MS program
4 years ago
FDA+
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
4 years ago
Deals
AI
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
5 years ago
FDA+
NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna's chief safety officer
5 years ago
Peer Review
Renegotiate the $6B CVR deal Bristol Myers made for the Celgene buyout? Caforio says that’s not happening
5 years ago
Deals
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet ...
5 years ago
FDA+
Bristol Myers hints at some problems with an FDA inspection needed for the liso-cel OK, and the Celgene CVR investors ...
5 years ago
R&D
FDA+
After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firm
5 years ago
People
Bristol Myers snares another approval from the old Celgene pipeline, nabbing an overlooked OK
5 years ago
Pharma
FDA+
Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms
5 years ago
Financing
China
Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive
5 years ago
News Briefing
1
2
3
4
Next page
Last page
latest
Most read
Trump says he'll sign order on 'most-favored nation' drug price plans Monday
6 hours ago
R&D
Pharma
Makary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most Favored Nations"; and more
Yesterday
Weekly
Chronic care startup Omada Health files to go public
2 days ago
Financing
Startups
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi
2 days ago
Pharma
Manufacturing
see latest stream
